Xanthomatous Giant Cell Renal Cell Carcinoma

Over the past decade, several distinct novel renal epithelial neoplasms driven by underlying tuberous sclerosis comples (TSC)/mammalian target of rapamycin (MTOR) pathway mutations have been described. We report herein two distinctive TSC2-mutated renal cell carcinomas which do not fit any previously described entity. The two renal carcinomas occurred in young patients (ages 10 and 31 y), and were characterized by highly permeative growth within the kidney with metastases to perirenal lymph nodes. The neoplastic cells were predominantly large, multinucleated giant cells having variably eosinophilic to xanthomatous cytoplasm with basophilic stippling and frequent vacuolization. While the discohesive nature of the neoplastic cells, xanthomatous cytoplasm, immunoreactivity for histiocytic markers and minimal immunoreactivity for conventional epithelial markers raised the possibility of a histiocytic neoplasm, multifocal immunoreactivity for cytokeratin 20 helped establish their epithelial nature. Despite the aggressive growth pattern of these neoplasms and lymph node metastases, mitotic figures were rare and Ki-67 indices were low (<1%). One patient with follow-up shows no evidence of disease seven years after nephrectomy with no adjuvant therapy. Next-generation sequencing demonstrated TSC2 mutations in each case. By immunohistochemistry, downstream markers of mTOR pathway activation S6K1, 4EBP1, and glycoprotein nonmetastatic melanoma protein B were all highly expressed in these neoplasms, suggesting mTOR pathway activation as the neoplastic driver. While the cytokeratin 20 immunoreactivity and focal basophilic cytoplasmic stippling suggest a relationship to eosinophilic solid and cystic renal cell carcinoma, and cytoplasmic vacuolization suggests a relationship to eosinophilic vacuolated tumor, these neoplasms appear to be distinctive given their permeative growth patterns and predominant xanthomatous giant cell morphology. Addition of cytokeratin 20 to a panel of epithelial markers helps avoid misdiagnosis in such cases.

[1]  P. Argani,et al.  GPNMB expression identifies TSC1/2/mTOR‐associated and MiT family translocation‐driven renal neoplasms , 2022, The Journal of pathology.

[2]  P. Argani,et al.  Renal cell carcinoma associated with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) genetic alterations , 2022, Modern Pathology.

[3]  Sourav K. Mishra,et al.  Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway , 2021, Modern Pathology.

[4]  M. Merad,et al.  Histiocytic disorders , 2021, Nature Reviews Disease Primers.

[5]  I. Pedrosa,et al.  Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney , 2021, Modern Pathology.

[6]  M. Sibony,et al.  Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1 , 2021, Modern Pathology.

[7]  J. Cheville,et al.  Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a Single Institutional Experience with Clinicopathological and Molecular Characteristics. , 2021, Human pathology.

[8]  T. Guzzo,et al.  Acquired Cystic Kidney Disease–associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes , 2020, The American journal of surgical pathology.

[9]  R. Shah,et al.  “Renal Cell Carcinoma With Leiomyomatous Stroma” Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity , 2019, The American journal of surgical pathology.

[10]  A. Sangoi,et al.  Low‐grade oncocytic tumour of kidney (CD117‐negative, cytokeratin 7‐positive): a distinct entity? , 2019, Histopathology.

[11]  Lauren L. Ritterhouse,et al.  Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma , 2019, The American journal of surgical pathology.

[12]  V. Reuter,et al.  Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm , 2019, The American journal of surgical pathology.

[13]  S. Dhanasekaran,et al.  Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. , 2018, European urology.

[14]  M. Bonert,et al.  “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases , 2018, Virchows Archiv.

[15]  P. Argani,et al.  Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum , 2018, The American journal of surgical pathology.

[16]  Lauren L. Ritterhouse,et al.  Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations? , 2018, The American journal of surgical pathology.

[17]  F. Algaba,et al.  Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  P. Argani,et al.  Re‐evaluation of 33 ‘unclassified’ eosinophilic renal cell carcinomas in young patients , 2018, Histopathology.

[19]  S. Hammes,et al.  Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target , 2017, Steroids.

[20]  D. Berney,et al.  Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity , 2017, The American journal of surgical pathology.

[21]  R. Varadhan,et al.  Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation , 2016, Leukemia.

[22]  C. Porta,et al.  Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.

[23]  A. Sangoi,et al.  Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women , 2016, The American journal of surgical pathology.

[24]  D. Grignon,et al.  Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity , 2015, Modern Pathology.

[25]  P. Argani,et al.  t(6;11) Renal Cell Carcinoma (RCC): Expanded Immunohistochemical Profile Emphasizing Novel RCC Markers and Report of 10 New Genetically Confirmed Cases , 2014, The American journal of surgical pathology.

[26]  E. Montgomery,et al.  A broad survey of cathepsin K immunoreactivity in human neoplasms. , 2013, American journal of clinical pathology.

[27]  A. Ziober,et al.  The Use of Immunohistochemical Expression of SF-1 and EMA in Distinguishing Adrenocortical Tumors From Renal Neoplasms , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[28]  M. Ladanyi,et al.  Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions , 2011, Modern Pathology.

[29]  A. Gown,et al.  Pure Epithelioid PEComas (So-Called Epithelioid Angiomyolipoma) of the Kidney: A Clinicopathologic Study of 41 Cases: Detailed Assessment of Morphology and Risk Stratification , 2011, The American journal of surgical pathology.

[30]  M. Ladanyi,et al.  PRCC-TFE3 Renal Carcinomas: Morphologic, Immunohistochemical, Ultrastructural, and Molecular Analysis of an Entity Associated With the t(X;1)(p11.2;q21) , 2002, The American journal of surgical pathology.

[31]  J. Blenis,et al.  Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. , 2002, Genes & development.

[32]  M. Ladanyi,et al.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. , 2001, The American journal of pathology.

[33]  M. Miettinen,et al.  Keratin subsets in spindle cell sarcomas. Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. , 1991, The American journal of pathology.